Equipo Ciencia will conduct a study to evaluate the efficacy, safety, and tolerability of a new drug in people with bronchiectasis. .
This chronic lung disease is characterized by abnormal and irreversible dilation of the airways, which hinders the proper clearance of mucus, leads to chronic fatigue, and causes recurrent lung infections.
The objective of this study is to identify whether this new treatment delays the progression of the disease, which would allow an improvement in the quality of life of those affected.
